• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.

作者信息

Jhaveri Kenar D, Rosner Mitchell H

机构信息

Division of Kidney Diseases and Hypertension, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York; and.

Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

出版信息

Clin J Am Soc Nephrol. 2018 May 7;13(5):796-798. doi: 10.2215/CJN.12871117. Epub 2018 Mar 9.

DOI:10.2215/CJN.12871117
PMID:29523675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5969488/
Abstract
摘要

相似文献

1
Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.嵌合抗原受体T细胞疗法与肾脏：肾病学家需要了解的内容。
Clin J Am Soc Nephrol. 2018 May 7;13(5):796-798. doi: 10.2215/CJN.12871117. Epub 2018 Mar 9.
2
Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.嵌合抗原受体 T 细胞疗法与肾毒性：从诊断到治疗策略。
Int Immunopharmacol. 2020 Dec;89(Pt B):107072. doi: 10.1016/j.intimp.2020.107072. Epub 2020 Oct 12.
3
Chimeric Antigen Receptor (CAR) T-Cell Therapy.嵌合抗原受体（CAR）T细胞疗法
JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989.
4
CAR T-cells for relapsed B-cell ALL in adults.用于成人复发B细胞急性淋巴细胞白血病的嵌合抗原受体T细胞
Lancet Oncol. 2018 Mar;19(3):e143. doi: 10.1016/S1470-2045(18)30086-X. Epub 2018 Feb 9.
5
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原免疫疗法对多发性骨髓瘤具有广阔的应用前景。
Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28.
6
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.嵌合抗原受体修饰 T 细胞治疗淋巴瘤。
Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z.
7
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞治疗 B 细胞急性淋巴细胞白血病。
Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018.
8
[Not Available].[无可用内容]
Bull Cancer. 2018 Dec;105 Suppl 2:S188-S197. doi: 10.1016/S0007-4551(19)30049-9.
9
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
10
Beginning the CAR T cell therapy revolution in the US and EU.开启美国和欧盟的嵌合抗原受体T细胞（CAR T）疗法革命。
Curr Res Transl Med. 2018 May;66(2):62-64. doi: 10.1016/j.retram.2018.03.004. Epub 2018 Apr 12.

引用本文的文献

1
Acute kidney injury: pathogenesis and therapeutic interventions.急性肾损伤：发病机制与治疗干预
Mol Biomed. 2025 Sep 5;6(1):61. doi: 10.1186/s43556-025-00293-4.
2
Cytokine release syndrome in solid tumors.实体瘤中的细胞因子释放综合征
Cancer. 2025 Sep 1;131(17):e70069. doi: 10.1002/cncr.70069.
3
Nephrotoxicity of immunotherapy and targeted therapies used to treat paediatric cancer.用于治疗儿童癌症的免疫疗法和靶向疗法的肾毒性。
Pediatr Nephrol. 2025 Jul 7. doi: 10.1007/s00467-025-06852-9.
4
Acute Kidney Injury Associated with Novel Anticancer Therapies: Immunotherapy.与新型抗癌疗法相关的急性肾损伤：免疫疗法
Kidney360. 2025 Apr 1;6(4):652-662. doi: 10.34067/KID.0000000749. Epub 2025 Feb 24.
5
Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes.CAR-T 细胞治疗血液系统疾病患者的急性肾损伤：危险因素、临床表现及对结局的影响。
Sci Rep. 2024 Nov 6;14(1):26886. doi: 10.1038/s41598-024-77720-z.
6
Acute kidney injury after CAR-T cell therapy: exploring clinical patterns, management, and outcomes.嵌合抗原受体T细胞疗法后的急性肾损伤：探索临床模式、管理及结局
Clin Kidney J. 2024 May 30;17(6):sfae123. doi: 10.1093/ckj/sfae123. eCollection 2024 Jun.
7
Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent, and young adult patients with B-cell acute lymphoblastic leukemia.儿童、青少年和年轻成人 B 细胞急性淋巴细胞白血病患者接受 CD19 特异性嵌合抗原受体 T 细胞治疗后的急性肾损伤。
Pediatr Nephrol. 2024 Aug;39(8):2495-2503. doi: 10.1007/s00467-024-06331-7. Epub 2024 Mar 20.
8
Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.血液系统恶性肿瘤患者接受嵌合抗原受体T细胞治疗后的短暂性急性肾损伤。
Clin Kidney J. 2024 Feb 20;17(3):sfae027. doi: 10.1093/ckj/sfae027. eCollection 2024 Mar.
9
Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia.儿童、青少年和年轻成年B细胞急性淋巴细胞白血病患者接受CD19特异性嵌合抗原受体T细胞疗法治疗后的急性肾损伤
Res Sq. 2023 Oct 6:rs.3.rs-3396661. doi: 10.21203/rs.3.rs-3396661/v1.
10
Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.与嵌合抗原受体（CAR）-T细胞疗法相关的不良事件全谱。
J Biomed Sci. 2023 Oct 21;30(1):89. doi: 10.1186/s12929-023-00982-8.